Theorem Clinical Research

PPD

PPD first to migrate data to the Oracle Health Sciences Cloud

Thursday, March 26, 2015 02:58 PM

PPD is the first company to migrate trials from an on-site installation of Oracle Health Sciences’ Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service—creating a highly available, centralized trial database that lowers costs, simplifies management, improves the accuracy of multi-CRO clinical trial data and accelerates studies.

More... »

Quest Diagnostics

Society for Clinical Research Sites expands relationship with Acurian

Friday, March 13, 2015 12:30 PM

The Society for Clinical Research Sites (SCRS), a Ellicott City, Md.-based global trade organization representing clinical research sites, has announced an expanded relationship with Acurian, a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.

More... »


Biosimilars Provide New Business Opportunities for Sites

Monday, March 9, 2015 08:00 AM

Significant factors involved in the growth and potential impact of biosimilars include budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for low-cost alternatives, an increasingly aging population, government initiatives and rising incidences of various diseases.

More... »

PharmaTimes clinical research awards to be presented Feb. 26

Thursday, February 12, 2015 03:33 PM

The 2015’s PharmaTimes Clinical Researcher of the Year—The Americas awards will be presented Feb. 26 in North Carolina.

More... »

PPD expands GMP laboratory in Ireland

Wednesday, January 21, 2015 12:59 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., has expanded its good manufacturing practices (GMP) operations in Athlone, Ireland, by adding a new, state-of-the-art laboratory for cell-based assays to its existing portfolio of services at the facility. The new lab provides GMP bioassay testing with dedicated areas to support cell culture activities with multiple assay endpoint expertise.

More... »

X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »

PPD, SNBL form Japanese clinical development joint venture

Monday, January 5, 2015 12:33 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and Japan-based Shin Nippon Biomedical Laboratories (SNBL) have formed a joint venture to provide a full range of clinical development services in Japan, including phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

More... »

PPD, ERT partner to enhance drug development

Wednesday, December 17, 2014 12:28 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and ERT, a Philadelphia, Pa.-based provider of patient safety and efficacy data collection solutions, have partnered to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.

More... »

PPD’s Randy Anderson named Health Care Hero for diabetes research

Thursday, November 20, 2014 12:49 PM

Randy Anderson, Ph.D., vice president of global product development and therapeutic area leader for metabolics at global CRO Pharmaceutical Product Development (PPD), was named a 2014 Health Care Hero. The annual awards honor members of the greater Wilmington medical community for their engagement on critical health issues.

More... »

PRA Health Sciences becomes latest big CRO to launch IPO

Thursday, November 13, 2014 03:38 PM

PRA Health Sciences launched its initial public offering this morning, raising $306 million from the sale of nearly 17 million shares at $18 per share—below plans it announced in September to raise up to $375 million.

More... »


CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs